Clinical Trial Update: A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the feasibility of combining romidepsin with brentuximab vedotin in cutaneous T-cell lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma

Drugs mentioned

• Adcetris (Brentuximab vedotin)
• Istodax (romidepsin)

Snippet

Sponsor: Fox Chase Cancer Center | Conditions: Cutaneous T-cell Lymphoma (CTCL) | Phase 1 | Status: COMPLETED